ARTICLE | Finance
Takeda gets Ambys-tious
Takeda finally gets the ball rolling in liver diseases with $140M Ambys deal
August 10, 2018 11:08 PM UTC
After a two-year search, Takeda Pharmaceutical Co. Ltd.’s equity investment and option deal with newco Ambys Medicines finally gets the ball rolling on the pharma’s goal of building a liver franchise within its core area of gastroenterology.
The way it solved the problem was by taking its trend of doing earlier and earlier deals to its logical conclusion -- company formation...